Herbal products use during pregnancy: prevalence and predictors.

Pharmacoepidemiol Drug Saf

Faculty of Pharmacy, University of Montreal, Quebec, Canada.

Published: June 2009

Purposes: (1) Measure the prevalence of herbal product (HP) use, alone, and concomitantly with prescribed medications during pregnancy, (2) identify the most frequently consumed HP during gestation and (3) determine predictors of HP use at the beginning of pregnancy, and during the third trimester.

Methods: A questionnaire was mailed to 8505 women selected from the Quebec Pregnancy Registry which was created by the linkage of three administrative databases: RAMQ, Méd-Echo and ISQ. Women were eligible if they were continuously insured by the RAMQ drug plan for at least 12 months before the first day of gestation and during pregnancy, and if they gave birth to a live born between January 1998 and December 2003 in one of the Quebec's hospitals. Women with diabetes and psychoses, and women who delivered a baby with birth defects were selected first. Descriptive statistics and multivariate logistic regression models were used to analyse data.

Results: Of the 3354 women (39%) who answered the questionnaire, and were included in the study, nine per cent used HP during pregnancy. 69% of users took at least one prescribed medication concomitantly. Chamomile, green tea, peppermint and flax were the most frequently HP used. Multivariate analyses showed that body mass index (BMI), multivitamin use and one to three prescribed medications used before pregnancy were predictors of HP use at the beginning of pregnancy; adherent women, smokers and users of HP prior to pregnancy were predictors of HP use during the third trimester.

Conclusion: HP use alone and concomitantly with prescribed medications during pregnancy is common, and needs to be addressed by health professionals.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pds.1731DOI Listing

Publication Analysis

Top Keywords

prescribed medications
12
medications pregnancy
12
pregnancy
10
concomitantly prescribed
8
predictors pregnancy
8
pregnancy predictors
8
women
6
herbal products
4
products pregnancy
4
pregnancy prevalence
4

Similar Publications

Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.

Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.

View Article and Find Full Text PDF

Factors Associated With Semaglutide Initiation Among Adults With Obesity.

JAMA Netw Open

January 2025

Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts.

Importance: Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, was approved for weight management in individuals with obesity in June 2021. There is limited evidence on factors associated with uptake among individuals in this subgroup without diabetes.

Objective: To explore factors associated with semaglutide initiation among a population of commercially insured individuals with obesity but no diagnosed diabetes.

View Article and Find Full Text PDF

Introduction: Patients with chronic inflammatory diseases are often treated with pharmacologic therapies that target the immune system and have an increased risk of infection. These risks can be reduced by vaccination against common pathogens. This quality improvement project aimed to increase pneumococcal and herpes zoster vaccination rates in patients with chronic inflammatory disease on biologic immunosuppressive therapy.

View Article and Find Full Text PDF

Introduction: Prescribable digital health applications (DiGAs) present scalable solutions to improve patient self-management in rheumatology, however real-world evidence is scarce. Therefore, we aimed to assess the effectiveness, usage, and usability of DiGAs prescribed by rheumatologists, as well as patient satisfaction.

Methods: The DiGAReal registry includes adult patients with rheumatic conditions who received a DiGA prescription.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!